Legis Daily

Chronic Kidney Disease Improvement in Research and Treatment Act of 2021

USA117th CongressHR-4065| House 
| Updated: 6/23/2021
Terri A. Sewell

Terri A. Sewell

Democratic Representative

Alabama

Cosponsors (9)
Stacey E. Plaskett (Democratic)Tom O'Halleran (Democratic)Steve Cohen (Democratic)Donald M. Payne (Democratic)Ann M. Kuster (Democratic)Eddie Bernice Johnson (Democratic)Brian K. Fitzpatrick (Republican)Rashida Tlaib (Democratic)Vern Buchanan (Republican)

Ways and Means Committee, Health Subcommittee, Health Subcommittee, Energy and Commerce Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 This bill modifies provisions relating to Medicare coverage of treatments for chronic kidney disease. Specifically, the bill expands the Medicare annual wellness visit to include chronic kidney disease screening and allows certain Medicare beneficiaries who have End Stage Renal Disease (ESRD) to enroll in Medicare supplemental policies. It also (1) provides for alternative payment methodologies for certain new drugs, biologics, and devices that are renal dialysis services; (2) revises quality measures; (3) establishes an incentive payment methodology; and (4) increases access to kidney disease education services. The bill also extends the coordination period (from 30 months to 42 months) during which private health insurers may serve as the primary payers for Medicare beneficiaries with ESRD.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline

Bill from Previous Congress

HR 116-3912
Chronic Kidney Disease Improvement in Research and Treatment Act
Jun 8, 2021

Latest Companion Bill Action

S 117-1971
Introduced in Senate
Jun 22, 2021
Introduced in House
Jun 22, 2021
Referred to the Subcommittee on Health.
Jun 22, 2021
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Jun 23, 2021
Referred to the Subcommittee on Health.
  • Bill from Previous Congress

    HR 116-3912
    Chronic Kidney Disease Improvement in Research and Treatment Act


  • June 8, 2021

    Latest Companion Bill Action

    S 117-1971
    Introduced in Senate


  • June 22, 2021
    Introduced in House


  • June 22, 2021
    Referred to the Subcommittee on Health.


  • June 22, 2021
    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.


  • June 23, 2021
    Referred to the Subcommittee on Health.

Health

Related Bills

  • S 117-1971: Chronic Kidney Disease Improvement in Research and Treatment Act of 2021
  • HR 117-1676: Jack Reynolds Memory Medigap Expansion Act
Administrative law and regulatory proceduresCongressional oversightDepartment of Health and Human ServicesDigestive and metabolic diseasesDrug therapyGovernment studies and investigationsHealth care costs and insuranceHealth care coverage and accessHealth care qualityHealth facilities and institutionsHealth promotion and preventive careHealth technology, devices, suppliesMedicaidMedical researchMedical tests and diagnostic methodsMedicareMinority healthOrgan and tissue donation and transplantationState and local government operations

Chronic Kidney Disease Improvement in Research and Treatment Act of 2021

USA117th CongressHR-4065| House 
| Updated: 6/23/2021
Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 This bill modifies provisions relating to Medicare coverage of treatments for chronic kidney disease. Specifically, the bill expands the Medicare annual wellness visit to include chronic kidney disease screening and allows certain Medicare beneficiaries who have End Stage Renal Disease (ESRD) to enroll in Medicare supplemental policies. It also (1) provides for alternative payment methodologies for certain new drugs, biologics, and devices that are renal dialysis services; (2) revises quality measures; (3) establishes an incentive payment methodology; and (4) increases access to kidney disease education services. The bill also extends the coordination period (from 30 months to 42 months) during which private health insurers may serve as the primary payers for Medicare beneficiaries with ESRD.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline

Bill from Previous Congress

HR 116-3912
Chronic Kidney Disease Improvement in Research and Treatment Act
Jun 8, 2021

Latest Companion Bill Action

S 117-1971
Introduced in Senate
Jun 22, 2021
Introduced in House
Jun 22, 2021
Referred to the Subcommittee on Health.
Jun 22, 2021
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Jun 23, 2021
Referred to the Subcommittee on Health.
  • Bill from Previous Congress

    HR 116-3912
    Chronic Kidney Disease Improvement in Research and Treatment Act


  • June 8, 2021

    Latest Companion Bill Action

    S 117-1971
    Introduced in Senate


  • June 22, 2021
    Introduced in House


  • June 22, 2021
    Referred to the Subcommittee on Health.


  • June 22, 2021
    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.


  • June 23, 2021
    Referred to the Subcommittee on Health.
Terri A. Sewell

Terri A. Sewell

Democratic Representative

Alabama

Cosponsors (9)
Stacey E. Plaskett (Democratic)Tom O'Halleran (Democratic)Steve Cohen (Democratic)Donald M. Payne (Democratic)Ann M. Kuster (Democratic)Eddie Bernice Johnson (Democratic)Brian K. Fitzpatrick (Republican)Rashida Tlaib (Democratic)Vern Buchanan (Republican)

Ways and Means Committee, Health Subcommittee, Health Subcommittee, Energy and Commerce Committee

Health

Related Bills

  • S 117-1971: Chronic Kidney Disease Improvement in Research and Treatment Act of 2021
  • HR 117-1676: Jack Reynolds Memory Medigap Expansion Act
  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Administrative law and regulatory proceduresCongressional oversightDepartment of Health and Human ServicesDigestive and metabolic diseasesDrug therapyGovernment studies and investigationsHealth care costs and insuranceHealth care coverage and accessHealth care qualityHealth facilities and institutionsHealth promotion and preventive careHealth technology, devices, suppliesMedicaidMedical researchMedical tests and diagnostic methodsMedicareMinority healthOrgan and tissue donation and transplantationState and local government operations